Sage Therapeutics Inc Total Assets
Sage Therapeutics Inc total assets. Based on the latest financial reports, Sage Therapeutics Inc (SAGE) holds total assets worth $422.92 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Sage Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of Sage Therapeutics Inc (2012–2024)
Total assets of Sage Therapeutics Inc from 2012 to 2024. This chart illustrates how Sage Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Sage Therapeutics Inc stock price for real-time trading data and today's change.
Sage Therapeutics Inc - Asset Composition Analysis
Sage Therapeutics Inc Total Assets Breakdown (December 2024)
Sage Therapeutics Inc total assets breakdown as of December 2024. Sage Therapeutics Inc's total assets of $422.92 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.8% |
| Accounts Receivable | $9.13 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Sage Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SAGE working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sage Therapeutics Inc's current assets represent 97.1% of total assets in 2024, an increase from 94.4% in 2012.
- Cash Position: Cash and equivalents constituted 14.8% of total assets in 2024, down from 93.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Sage Therapeutics Inc Competitors by Total Assets
Key competitors of Sage Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Sage Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.16 | 9.95 | 11.71 |
| Quick Ratio | 9.16 | 9.95 | 11.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $364.44 Million | $617.77 Million | $639.22 Million |
Sage Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sage Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -38.0% |
| Total Assets | $547.22 Million |
| Market Capitalization | $544.94 Million USD |
Valuation Analysis
Near Book Valuation: The market values Sage Therapeutics Inc's assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Sage Therapeutics Inc's assets decreased by 38.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sage Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Sage Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $547.22 Million | -37.98% |
| 2023-12-31 | $882.28 Million | -34.96% |
| 2022-12-31 | $1.36 Billion | -25.69% |
| 2021-12-31 | $1.83 Billion | -15.47% |
| 2020-12-31 | $2.16 Billion | +99.16% |
| 2019-12-31 | $1.08 Billion | +13.80% |
| 2018-12-31 | $952.71 Million | +79.78% |
| 2017-12-31 | $529.94 Million | +31.00% |
| 2016-12-31 | $404.53 Million | +114.02% |
| 2015-12-31 | $189.02 Million | +45.77% |
| 2014-12-31 | $129.66 Million | +1419.75% |
| 2013-12-31 | $8.53 Million | +184.87% |
| 2012-12-31 | $3.00 Million | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more